Effects of treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11

Objective:To investigate the effects of treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11(rhIL-11). Methods:Thirty-six patients of carcinoma with chemotherapy-induced thrombocytopenia were divided into two groups:group A (19 cases) and group B (17 cases). Patients of group A were treated with rhIL-11,1.5mg daily,injected hypodermicly for 5 ~12 days ; patients of group B were treated with conventional regime. Platelet count was observed weekly for three weeks. Results:Platelet count in group A and B were(42.00±12.29)×109 L-1 ,(44.58±11.74)×109 L-1 and (192.00±73.56)×109 L-1,(203.37±75.28)×109 L-1 after and before chemotherapy respectively,compared them with those before chemotherapy ,all decreased after chemotherapy (P0.05). After therapy,platelet count increased and gradually recovered to normal level,the normalization rates of platelet count in group A and B were 42.11% ,0 % and 100.00%,11.76% in the first and second week respectively,the differences between them were significant (P﹤0.01). Patients of group A tolerated well,no obvious nausea,vomiting,diarrhea and other adverse reactions took place. Conclusion:Treatment of chemotherapy-induced thrombocytopenia in patients of carcinoma with recombinant human interleukin-11 was safe and effective.